Pre-natal Tests on Net a Threat
By Indo-Asian News Service,
Indo-Asian News Service
| 03. 15. 2008
New Delhi: The advent of Internet has emerged as a new threat as overseas agencies are posting advertisements for sex determination services and equipment that can be used at home, Health Minister Anbumani Ramadoss has said.
Ramadoss informed the Rajya Sabha of the websites offering such services - www.4-gender-selection.com, www.pregnancystore.com and others which offer sex determination kits called the 'baby Gender Mentor Home DNA Test Kit'.
These sites help the customer determine the sex of the foetus through DNA analysis at home.
The house was also told Friday that gender testing kits from the US and Canada were available in certain markets in Punjab for Rs.15-20,000. It was also found that some genetic centres were importing kits online in response to advertisements.
The matter was referred to the Ministry of Communications and IT in order to block the offending websites.
He was told by the ministry that blocking the websites was not totally successful as "they could re-emerge and be available for the viewers again under a new nomenclature and in a new avatar," Ramadoss said.
The issue has...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...